e-learning
resources
Vienna 2012
Monday, 03.09.2012
Pulmonary circulation: end-points and biomarkers
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Asymmetric dimethylarginine, a biomarker for the effects of drug therapy in pulmonary hypertension
N. Skoro-Sajer, G. Hlavin, S. Aschauer, M. Wolzt, I. Lang (Austria)
Source:
Annual Congress 2012 - Pulmonary circulation: end-points and biomarkers
Session:
Pulmonary circulation: end-points and biomarkers
Session type:
Oral Presentation
Number:
2831
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. Skoro-Sajer, G. Hlavin, S. Aschauer, M. Wolzt, I. Lang (Austria). Asymmetric dimethylarginine, a biomarker for the effects of drug therapy in pulmonary hypertension. Eur Respir J 2012; 40: Suppl. 56, 2831
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Asymmetric dimethylarginine (ADMA) to monitor treatments of pulmonary hypertension
Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension
Year: 2019
Biomarkers in pulmonary hypertension
Source: Eur Respir J 2008; 32: 503-512
Year: 2008
The association between pulmonary arterial hypertension secondary to chronic lung disease and serum asymmetric dimethylarginine levels
Source: Annual Congress 2012 - COPD comorbidities II
Year: 2012
Attenuated expression and activity of dimethylarginine dimethylaminohydrolase may play a key role in monocrotaline-induced pulmonary hypertension by accumulation of endogenous NOS inhibitors in rats
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
The role of asymmetric dimethylarginine (ADMA) in patients with asthma
Source: Virtual Congress 2021 – Biomarkers for the management of bronchial obstructive diseases
Year: 2021
Asymmetric dimethylarginine and asthma
Source: Eur Respir J 2014; 43: 647-648
Year: 2013
Metabolic dysfunction associated with redox imbalance in pulmonary hypertension: Effects of the prolonged sildenafil use
Source: International Congress 2016 – Pulmonary hypertension in lung disease
Year: 2016
Asymmetric dimethylarginine contributes to airway nitric oxide deficiency in patients with COPD
Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease
Year: 2015
Predictors of response to phosphodiesterase-5 inhibitors in pulmonary arterial hypertension
Source: Virtual Congress 2021 – Therapy of pulmonary hypertension
Year: 2021
Pulmonary hypertension: future therapies
Source: ISSN=1025-448x, ISBN=1-904097-31-6, page=84
Year: 2004
Circulating endothelial cell levels decrease after vasodilator therapy and are a biomarker of clinical worsening in refractory pulmonary hypertension in children
Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH
Year: 2012
Ventilation-perfusion relationships in severe pulmonary hypertension. Effects of acute and long-term treatment with prostacyclin
Source: Eur Respir J 2001; 18: Suppl. 33, 253s
Year: 2001
Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy
Source: Eur Respir Rev 2009; 18: 253-259
Year: 2009
Inhaled iloprost did not influence cytokines levels in patients with different forms of pulmonary hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
Impact of therapies on insulin resistance in pulmonary arterial hypertension
Source: Annual Congress 2010 - Pulmonary circulation: clinical aspects
Year: 2010
Long-term outcomes in incident pulmonary arterial hypertension (PAH) patients initiated with triple combination therapy including parenteral prostacyclin (PGI2)
Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension
Year: 2020
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors
Source: Eur Respir J, 50 (3) 1602425; 10.1183/13993003.02425-2016
Year: 2017
Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension
Source: Eur Respir J, 57 (4) 2003201; 10.1183/13993003.03201-2020
Year: 2021
Endothelin-1 and endothelin-3 plasma levels in severe idiopathic pulmonary arterial hypertension
Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology
Year: 2005
Comparison of acute hemodynamic effects of three different phosphodiesterase inhibitors in patients with pulmonary arterial hypertension
Source: Eur Respir J 2004; 24: Suppl. 48, 705s
Year: 2004
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept